Biophytis (EPA:ALBPS) | Finanzwire

Basculer en Français

10357	Companies
215527	Keywords
145336	Articles
114173	Press releases

Home
Companies
Biophytis

REGULATED PRESS RELEASE

published on 04/08/2024 at 23:12, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results and business update, highlighting progress in clinical programs and partnerships. CEO Stanislas Veillet shares insights on growth strategies and collaborations

Financial Results Biophytis Partnerships Clinical Programs Growth Strategies
REGULATED PRESS RELEASE

published on 04/08/2024 at 23:10, 2 years ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA Phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone), aiming to address muscle loss from obesity treatment and promising results in preclinical studies. Clinical study expected to start mid-2024 with results in 2025

Biophytis Clinical Study BIO101 OBA Phase 2 Obesity
BRIEF

published on 04/08/2024 at 23:09, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its activities

Biophytis Funding Clinical Development 2023 Financial Results BIO101
BRIEF

published on 04/08/2024 at 23:05, 2 years ago

Biophytis Announces Phase 2 Clinical Study in Obesity Treatment with BIO101

Biophytis Obesity Treatment BIO101 OBA Phase 2 Clinical Study GLP-1 Receptor Agonists
PRESS RELEASE

published on 04/08/2024 at 23:04, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & updates business activities. Successfully developing clinical programmes & obtaining FDA approval for SARA-31 trial in sarcopenia

Biophytis FDA Approval 2023 Financial Results Clinical Programmes SARA-31 Trial
PRESS RELEASE

published on 04/08/2024 at 23:01, 2 years ago

Biophytis announces its 2023 financial results and provides an update on its business activities
Biophytis announces 2023 financial results & business update. Highlights: progress in clinical programmes, funding secured till 2025. Key focus on SARA, OBA, COVA, OBA, and MYODA programs

Financial Results Biophytis 2023 Funding Clinical Programmes
PRESS RELEASE

published on 04/08/2024 at 23:00, 2 years ago

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)
Biophytis launches OBA phase 2 clinical study with BIO101 (20-hydroxyecdysone) for obesity treatment, targeting muscle preservation and promising results. Clinical program expected to start mid-2024

Biophytis Obesity Treatment BIO101 OBA Phase 2 Muscle Preservation
BRIEF

published on 04/04/2024 at 23:05, 2 years 1 month ago

Biophytis Announces Unanimous Approval in General Meeting

Biophytis Shareholder Approval General Meeting RuvembriTM Age-related Diseases
PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 1 month ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces all resolutions presented at the combined general meeting on April 2, 2024, have been adopted, including financial delegations. Shareholders' mobilization ensured a quorum of nearly 30%

Shareholders Biophytis General Meeting Resolutions Approval
REGULATED PRESS RELEASE

published on 04/04/2024 at 23:00, 2 years 1 month ago

RESULTS OF THE COMBINED GENERAL MEETING ON APRIL 2, 2024
Biophytis announces approval of all resolutions at the Combined General Meeting held on April 2, 2024, with significant shareholder turnout. The Company specializes in therapeutics for age-related diseases

Shareholders Biophytis Therapeutics Combined General Meeting Age-related Diseases

Accesswire

Published on 05/07/2026 at 05:40, 1 hour 18 minutes ago

New Horizon Aircraft Ltd. Announces Pricing of $20 Million Offering of Common Shares
Published on 05/07/2026 at 02:00, 4 hours 58 minutes ago

Lobe Sciences Ltd. Announces Participation in the D. Boral Capital Global Conference in New York
Published on 05/06/2026 at 23:30, 7 hours 28 minutes ago

Stabilis Solutions Announces First Quarter 2026 Results
Published on 05/06/2026 at 23:05, 7 hours 53 minutes ago

Zomedica Announces Record First Quarter Revenue of $8.8 Million, Reflecting 35% Annual Growth; and $47.5 Million in Liquidity
Published on 05/06/2026 at 23:00, 7 hours 58 minutes ago

Green Bridge Metals Strengthens Technical and Strategic Team as 2026 Work Programs Advance

View all ACCESSWIRE

EQS Group

Published on 05/07/2026 at 06:30, 28 minutes ago

Avolta reports a positive first quarter 2026, proving its resilience
Published on 05/07/2026 at 06:30, 28 minutes ago

Siegfried included in Dow Jones Best-in-Class Europe Index
Published on 05/07/2026 at 06:15, 43 minutes ago

Bison Bank, wholly owned by Hong Kong's Bison Capital, launches its MiCA-compliant stablecoin for institutional cross-border payments
Published on 05/07/2026 at 04:00, 2 hours 58 minutes ago

CUHK Claims Top Positions in Hong Kong and Asia in the Latest QS World University Rankings by Subject
Published on 05/07/2026 at 03:50, 3 hours 8 minutes ago

450 MHz LTE: Stronger, Smarter Grid for Brazil

Les Echos

Published on 05/06/2026 at 18:00, 12 hours 58 minutes ago

Access to information in respect of the General Shareholders’ Meeting to be held on June 4, 2026
Published on 05/06/2026 at 18:00, 12 hours 58 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of April 30, 2026
Published on 05/06/2026 at 17:45, 13 hours 13 minutes ago

Information concerning the total number of voting rights and shares 2026 04 30
Published on 05/06/2026 at 17:45, 13 hours 13 minutes ago

Declaration of voting rights at the end of April 2026
Published on 05/06/2026 at 17:45, 13 hours 13 minutes ago

Accor - Information regarding availability and consultation of preparatory documents - Shareholders' Meeting of May 27, 2026

View all LES ECHOS COMFI WIRE